Replies

Comments on research about a study on Astrazeneca I just reviewed from a layman's perspective (I ain't no doctor).

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

List of authors.

Andreas Greinacher, M.D.,
Thomas Thiele, M.D.,
Theodore E. Warkentin, M.D.,
Karin Weisser, Ph.D.,

Paul A. Kyrle, M.D.,

and Sabine Eichinger, M.D.

April 9, 2021

DOI: 10.1056/NEJMoa2104840

Pasted from <https://www.nejm.org/doi/full/10.1056/NEJMoa2104840?query=recirc_mostViewed_railB_article>

ransomnote:

The researchers describe the blood-clotting issue seen in several post vaccination cases for Astrazeneca as being similar to clotting that also occurs in some as a result of exposure to heparin. The onset for this reaction post vaccination is approximately 1 to 2 weeks.

A case study (49 year old health care worker) in their research had minor symptoms common to many I've read in the first 3 days following vaccination (fatigue, myalgia, and headache). Beginning on day 5, she had chills, fever, nausea, and epigastric discomfort; and was admitted to a local hospital on day 10.

As a result of their work, the researchers suggest providing non-heparin anti-coagulant to vaccination patients experiencing clotting, unless the patient has already been screened for adverse reaction to heparin in advance. I think this is an important finding because witnessing stroke-like symptoms in the ER likely results in the administration of Heparin, which for some may compound the clotting.

While their work was conducted only on Astrazeneca, I've read many accounts for Pfizer/Moderna of doctors grappling with 'stroke-like' symptoms in which clots may not be be found (a detail described in the linked research), clots, or evidence of 'cerebralvasdcular accidents.'

Data in VAERS today for "cereberalvascular accidents" Pfizer (49) and Moderna (40) and Johnson & Johnson (7). There are other terms used in the database to indicate clotting and thickening in the blood that doesn't necessary last but can cause things like brain damage during the time it's present, or which results in death.

Two quotes from their conclusions:

"Vaccination with ChAdOx1 nCov-19 can result in the rare development of immune thrombotic thrombocytopenia mediated by platelet-activating antibodies against PF4, which clinically mimics autoimmune heparin-induced thrombocytopenia. (Funded by the German Research Foundation.)"

SNIP

"Finally, we suggest naming this novel entity vaccine-induced immune thrombotic thrombocytopenia (VITT) to avoid confusion with heparin-induced thrombocytopenia."